SCHEMBL4076582

SCHEMBL4076582

Cc1cc(N(C)C)c2cc(Nc3nc(Nc4ccc5nc(C)cc(N(C)C)c5c4)nc(N4CCCN(C)CC4)n3)ccc2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 8/20 0.59
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
BLM P54132 1/20 0.49
HTR3A P46098 2/20 0.44
DHFR P00374 1/20 0.44
SYK P43405 1/20 0.44
HTT P42858 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
ADRA2C P18825 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DNMT1 P26358 1/20 0.42
RAD52 P43351 1/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4074849 0.96 TERT (0.64) TERTMEN1KMT2ABLMHTR3A
SCHEMBL6616885 0.85 TERT (0.58) TERTHTTADRA2AADRA2BADRA2C
SCHEMBL4082007 0.84 TERT (0.59) TERTMEN1KMT2ASYKADRA2A
SCHEMBL4076905 0.82 TERT (0.55) TERTMEN1KMT2ABLMDHFR
SCHEMBL4081924 0.81 TERT (0.53) TERTBLMHTTLMNARAD52
SCHEMBL4073115 0.79 TERT (0.61) TERTSYK
SCHEMBL4073592 0.78 TERT (0.59) TERTSYK
SCHEMBL6614253 0.77 TERT (0.61) TERTMEN1KMT2ABLMDHFR
SCHEMBL4076919 0.75 TERT (1.00) TERTMEN1KMT2AMAPTMAPK1
SCHEMBL6614255 0.75 TERT (0.61) TERTMEN1KMT2AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887873-B2 Triazine derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-05-03 US claimed
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent AVENTIS PHARMA S.A. (FR) 2003-05-08 US claimed
US-20090226411-A1 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS AVENTIS PHARMA S.A. (FR) 2009-09-10 US disclosed
US-7482352-B2 Chemical derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2009-01-27 US disclosed
US-6887873-B2 Triazine derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-05-03 US disclosed
US-20050070571-A1 Chemical derivatives and their application as antitelomerase agents AVENTIS PHARMA S.A. (FR) 2005-03-31 US disclosed
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent AVENTIS PHARMA S.A. (FR) 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087931-A1 Chemical derivatives and their application as antitelomerease agent DNASE1L3, SERPINB1, BRDT TERT 43/4885MEN1 3983/4885KMT2A 2224/4885
US-20090226411-A1 CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS DPYD, NTPCR, NME1 TERT 196/4885MEN1 4234/4885KMT2A 2886/4885
US-20050070571-A1 Chemical derivatives and their application as antitelomerase agents DPYD, NTPCR, NME1 TERT 196/4885MEN1 4234/4885KMT2A 2886/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.